Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to "Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study)" [The Lancet Regional Health - Europe 41 (2024) 100915].
Demoly P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Devillier P. Demoly P, et al. Among authors: collin c. Lancet Reg Health Eur. 2024 Oct 22;46:101120. doi: 10.1016/j.lanepe.2024.101120. eCollection 2024 Nov. Lancet Reg Health Eur. 2024. PMID: 39498359 Free PMC article.
Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study).
Demoly P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Devillier P. Demoly P, et al. Among authors: collin c. Lancet Reg Health Eur. 2024 Apr 26;41:100915. doi: 10.1016/j.lanepe.2024.100915. eCollection 2024 Jun. Lancet Reg Health Eur. 2024. PMID: 38707866 Free PMC article.
A successful linkage of a named patient products of sublingual immunotherapy-dispensing registry to French healthcare insurance database (SNDS): methodological constitution of the EfficAPSI cohort.
Devillier P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Demoly P. Devillier P, et al. Among authors: collin c. Expert Rev Clin Immunol. 2024 Apr;20(4):405-412. doi: 10.1080/1744666X.2023.2294040. Epub 2023 Dec 19. Expert Rev Clin Immunol. 2024. PMID: 38112340 Free article.
Cluster randomised controlled trial of double-dose azithromycin mass drug administration, facial cleanliness and fly control measures for trachoma control in Oromia, Ethiopia: the stronger SAFE trial protocol.
Last AR, Shafi Abdurahman O, Greenland K, Robinson A, Collin C, Czerniewska A, Etu ES, Versteeg B, Butcher R, Guye M, Legesse D, Nuri KT, Shuka G, Haji Mohammed Yousuf M, Dheressa G, Dumessa G, Akalu M, Tadesse M, Adugna Kumsa D, Seife Gebretsadik F, Abashawl A, Habtamu E, Sarah V, Alemayehu W, Solomon A, Weiss HA, Logan JG, Macleod D, Burton MJ. Last AR, et al. Among authors: collin c. BMJ Open. 2024 Dec 23;14(12):e084478. doi: 10.1136/bmjopen-2024-084478. BMJ Open. 2024. PMID: 39719287 Free article.
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
Chevallier P, Leguay T, Delord M, Salek C, Kim R, Huguet F, Hicheri Y, Wartiovaara-Kautto U, Raffoux E, Cluzeau T, Balsat M, Roth-Guepin G, Tavernier E, Lepretre S, Bilger K, Bergugnat H, Berceanu A, Alexis M, Doubek M, Brissot E, Hunault-Berger M, Lebon D, Turlure P, Chantepie S, Belhabri A, Wickenhauser S, Bastie JN, Cacheux V, Himberlin C, Banos A, Gardin C, Bonnet S, Plantier I, Pica GM, Escoffre-Barbe M, Boissel N, Dombret H, Clappier E, Rousselot P; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) and the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL). Chevallier P, et al. J Clin Oncol. 2024 Dec 20;42(36):4327-4341. doi: 10.1200/JCO.24.00490. Epub 2024 Oct 17. J Clin Oncol. 2024. PMID: 39418626 Clinical Trial.
278 results